These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38110665)

  • 1. A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer.
    Chen B; Yao W; Li X; Lin G; Chu Q; Liu H; Du Y; Lin J; Duan H; Wang H; Xiao Z; Sun H; Liu L; Xu L; Xu Y; Xu F; Kong Y; Pu X; Li K; Wang Q; Li J; Li B; Xia Y; Wu L
    Br J Cancer; 2024 Feb; 130(3):450-456. PubMed ID: 38110665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study).
    Zhao Y; Ma Y; Fan Y; Zhou J; Yang N; Yu Q; Zhuang W; Song W; Wang ZM; Li B; Xia Y; Zhao H; Zhang L
    Lung Cancer; 2023 Oct; 184():107355. PubMed ID: 37677918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC.
    Wang L; Luo Y; Ren S; Zhang Z; Xiong A; Su C; Zhou J; Yu X; Hu Y; Zhang X; Dong X; Meng S; Wu F; Hou X; Dai Y; Song W; Li B; Wang ZM; Xia Y; Zhou C
    J Thorac Oncol; 2024 Mar; 19(3):465-475. PubMed ID: 37879536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study.
    Lou H; Cai H; Huang X; Li G; Wang L; Liu F; Qin W; Liu T; Liu W; Wang ZM; Li B; Xia Y; Wang J
    Clin Cancer Res; 2024 Apr; 30(8):1501-1508. PubMed ID: 38372727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC.
    Chu T; Zhong R; Zhong H; Zhang B; Zhang W; Shi C; Qian J; Zhang Y; Chang Q; Zhang X; Dong Y; Teng J; Gao Z; Qiang H; Nie W; Zhao Y; Han Y; Chen Y; Han B
    J Thorac Oncol; 2021 Apr; 16(4):643-652. PubMed ID: 33524601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer.
    Chen C; Chen M; Bai Y; Li Y; Peng J; Yao B; Feng J; Zhou JG; Ma H
    Technol Cancer Res Treat; 2024; 23():15330338241249690. PubMed ID: 38706247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of the tyrosine kinase inhibitor anlotinib combined with platinum/pemetrexed-based chemotherapy in untreated nonsquamous non-small-cell lung cancer.
    Huang M; Liu Y; Yu M; Li Y; Zhang Y; Zhu J; Li L; Lu Y
    Invest New Drugs; 2022 Apr; 40(2):308-313. PubMed ID: 34724131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors.
    Frentzas S; Gan HK; Cosman R; Coward J; Tran B; Millward M; Zhou Y; Wang W; Xia D; Wang ZM; Li B; Xia M; Desai J
    Cell Rep Med; 2023 Nov; 4(11):101242. PubMed ID: 37852261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial.
    Qiao Q; Han C; Ye S; Li J; Shao G; Bai Y; Xu A; Sun M; Wang W; Wu J; Huang M; Song L; Huang L; Liu T; Liu W; Wang ZM; Li B; Xia M; Bai L
    Front Immunol; 2023; 14():1238667. PubMed ID: 37942328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors.
    Ma Y; Xue J; Zhao Y; Zhang Y; Huang Y; Yang Y; Fang W; Guo Y; Li Q; Ge X; Sun J; Zhang B; Zhang Y; Xiao J; Zhang L; Zhao H
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37263673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anlotinib Combined with S-1 in Third- or Later-Line Stage IV Non-Small Cell Lung Cancer Treatment: A Phase II Clinical Trial.
    Xiang M; Yang X; Ren S; Du H; Geng L; Yuan L; Wen Y; Lin B; Li J; Zhang Y; Feng G; Du X
    Oncologist; 2021 Dec; 26(12):e2130-e2135. PubMed ID: 34423518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sintilimab plus anlotinib as second- or third-line therapy in metastatic non-small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single-arm, phase II trial.
    Chen K; Xu Y; Huang Z; Yu X; Hong W; Li H; Xu X; Lu H; Xie F; Chen J; Xu Y; Fan Y
    Cancer Med; 2023 Oct; 12(19):19460-19470. PubMed ID: 37723837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer.
    Cho BC; Yoh K; Perets R; Nagrial A; Spigel DR; Gutierrez M; Kim DW; Kotasek D; Rasco D; Niu J; Satouchi M; Ahn MJ; Lee DH; Maurice-Dror C; Siddiqi S; Ren Y; Altura RA; Bar J
    Lung Cancer; 2021 Sep; 159():162-170. PubMed ID: 34371366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study.
    Zhang L; Wang L; Wang J; Chen J; Meng Z; Liu Z; Jiang X; Wang X; Huang C; Chen P; Liang Y; Jiang R; Wang J; Zhong D; Shang Y; Zhang Y; Zhang C; Huang D
    Mol Cancer; 2023 Aug; 22(1):124. PubMed ID: 37543587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anlotinib Combined with S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial.
    Yang X; Xiang M; Geng L; Wen Y; Du X
    Asian Pac J Cancer Prev; 2019 Dec; 20(12):3849-3853. PubMed ID: 31870132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anlotinib or platinum-pemetrexed as second-line therapy in EGFR T790M-negative lung cancer.
    Zhong RB; Xu JL; Lou YQ; Chu TQ; Zhong H; Han BH
    Ann Palliat Med; 2020 Jul; 9(4):1681-1687. PubMed ID: 32575999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.
    Zhang X; Zeng L; Li Y; Xu Q; Yang H; Lizaso A; Mao X; Jin R; Zeng Y; Li Q; Wang J; Li Y; Zhang Y; Yang N
    Cancer Immunol Immunother; 2021 Sep; 70(9):2517-2528. PubMed ID: 33566148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
    Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
    Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study.
    Chu T; Zhang W; Zhang B; Zhong R; Zhang X; Gu A; Shi C; Wang H; Xiong L; Lu J; Qian J; Zhang Y; Dong Y; Teng J; Gao Z; Wang W; Shen Y; Nie W; Lim JU; Mehta HJ; Neal JW; Lou Y; Xu J; Zhong H; Han B
    Transl Lung Cancer Res; 2022 Jul; 11(7):1394-1404. PubMed ID: 35958322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors.
    Zhao Y; Ma Y; Zang A; Cheng Y; Zhang Y; Wang X; Chen Z; Qu S; He J; Chen C; Jin C; Zhu D; Li Q; Liu X; Su W; Ba Y; Hao Y; Chen J; Zhang G; Qu S; Li Y; Feng W; Yang M; Liu B; Ouyang W; Liang J; Yu Z; Kang X; Xue S; Yang G; Yan W; Yang Y; Liu Z; Peng Y; Fanslow B; Huang X; Zhang L; Zhao H
    J Hematol Oncol; 2023 May; 16(1):50. PubMed ID: 37158938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.